bluebird bio, Inc. - Common Stock (NQ:BLUE)

4.970 UNCHANGED

Last Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about bluebird bio, Inc. - Common Stock

< Previous 1 2

...

16 17 18 19 20 21 22 23 Next >

bluebird bio Announces Positive Recommendation by PRAC Regarding Article 20 Safety Referral Review of ZYNTEGLO™ Gene Therapy for Transfusion-Dependent β-thalassemia and Marketing to Resume in EU

July 09, 2021

From bluebird bio, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For July 1, 2021 ↗

July 01, 2021

Upgrades Citigroup upgraded the previous rating for Thor Industries Inc (NYSE:

Via Benzinga

Will This 2020 Biotech IPO Crush the Market This Year? ↗

June 29, 2021

Legend Biotech's CAR-T therapy's trial results were amazing, and could earn the treatment FDA approval in 2021.

Via The Motley Fool

Topics Initial Public Offering

Is bluebird bio's Surge a Bellwether for Gene Editing Stocks? ↗

June 15, 2021

With safety concerns allayed, the company is ready to restart clinical trials of key therapies.

Via The Motley Fool

BLUEBIRD BIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of bluebird bio, Inc. - BLUE

June 11, 2021

From Kahn Swick & Foti, LLC

Via Business Wire

betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for β-thalassemia Continues to Demonstrate Durable Efficacy Across Pediatric and Adult Patient Populations and All Genotypes in Data Presented at EHA2021 Virtual

June 11, 2021

From bluebird bio, Inc.

Via Business Wire

Bluebird bio Can Restart Halted Clinical Trials ↗

June 07, 2021

The FDA has lifted the hold on bluebird bio's gene-therapy studies in sickle cell disease and transfusion-dependent β-thalassemia.

Via The Motley Fool

bluebird bio to Present at Goldman Sachs Global Healthcare Conference

June 07, 2021

From bluebird bio, Inc.

Via Business Wire

Bluebird Bio Pops As FDA Allows In-Human Gene Therapy Testing To Resume ↗

June 07, 2021

The FDA removed a hold barring Bluebird Bio from testing its blood-disease gene therapies in people on Monday, and BLUE stock surged.

Via Investor's Business Daily

FDA Gives Signal to Halted Bluebird Bio's Gene Therapy Trials In Sickle Cell Disease, Thalassemia ↗

June 07, 2021

The FDA has lifted the clinical hold on Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of Bluebird Bio Inc's (NASDAQ: BLUE) LentiGlobin for sickle cell...

Via Benzinga

bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies

June 07, 2021

From bluebird bio

Via Business Wire

The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck ↗

June 07, 2021

Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,...

Via Benzinga

bluebird bio, Inc. Reports Inducement Grants to CCO Tom Klima Under Nasdaq Listing Rule 5635(c)(4)

June 02, 2021

From bluebird bio, Inc.

Via Business Wire

Is bluebird bio a Buy for Summer 2021? ↗

May 25, 2021

With the stock down 54% over the past year, will investors be catching a falling knife if they buy now?

Via The Motley Fool

Bluebird bio's Neurological Disorder Gene Therapy Wins CHMP Backing for Approval ↗

May 21, 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorizations for Bluebird bio Inc’s...

Via Benzinga

bluebird bio Receives Positive CHMP Opinion for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age with Early Cerebral Adrenoleukodystrophy (CALD)

May 21, 2021

From bluebird bio, Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

May 20, 2021

Gainers Enveric Biosciences (NASDAQ:ENVB)...

Via Benzinga

Long-Term Data from Pivotal KarMMa Study Continue to Demonstrate Deep and Durable Responses and Predictable Safety Profile with Bristol Myers Squibb and bluebird bio’s Abecma (idecabtagene vicleucel) in Relapsed or Refractory Multiple Myeloma

May 19, 2021

From Bristol Myers Squibb

Via Business Wire

bluebird bio to Present Data from Its Severe Genetic Disease and Oncology Portfolios During the EHA2021 Virtual Congress

May 13, 2021

From bluebird bio, Inc.

Via Business Wire

NASDAQ:BLUE Long Term Investor Alert: Investigation of Potential Wrongdoing at Bluebird Bio Inc ↗

May 12, 2021

San Diego, CA -- (SBWIRE) -- 05/12/2021 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors of bluebird bio Inc.

Via SBWire

Topics Lawsuit

bluebird bio Reports First Quarter Financial Results and Highlights Operational Progress

May 05, 2021

From bluebird bio, Inc.

Via Business Wire

bluebird bio Announces May Investor Events

May 03, 2021

From bluebird bio, Inc.

Via Business Wire

What Investors Need to Know About This $419,500 CAR-T Cancer Treatment ↗

May 01, 2021

Abecma is on the market.

Via The Motley Fool

Will Vertex's Sickle Cell Gambit Sink bluebird bio's Stock? ↗

May 01, 2021

The competition is starting to heat up, but bluebird is far from finished.

Via The Motley Fool

bluebird bio Provides Update on Severe Genetic Disease Programs and Business Operations

April 20, 2021

From bluebird bio, Inc.

Via Business Wire

Is bluebird bio a Bad News Buy? ↗

April 14, 2021

The biotech has had a rough couple of years.

Via The Motley Fool

DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

April 13, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

April 12, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

TUESDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

April 09, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. (BLUE)

April 09, 2021

From The Law Offices of Frank R. Cruz

Via Business Wire

< Previous 1 2

...

16 17 18 19 20 21 22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.